Aptevo Therapeutics Shares Gain After First Dosed Patient in AML Trial Shows 90% Reduction in Leukemic Blasts
Aptevo Therapeutics Shares Gain After First Dosed Patient in AML Trial Shows 90% Reduction in Leukemic Blasts
Aptevo therapeutics的股票在首次给予患者的急性髓性白血病（AML）临床试验中，患者的白血病母细胞减少90%后获得涨幅。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册
资讯热榜
更新时间